...
首页> 外文期刊>Annals of Medicine and Surgery >Acute acalculous cholecystitis on a COVID-19 patient: a case report
【24h】

Acute acalculous cholecystitis on a COVID-19 patient: a case report

机译:Covid-19患者急性胆囊炎:案例报告

获取原文
   

获取外文期刊封面封底 >>

       

摘要

IntroductionWe report an extremely rare case of acute acalculous cholecystitis on a COVID-19 patient. In our knowledge, this is the first report of laparoscopic cholecystectomy performed on a COVID-19 patient.Presentation of caseA COVID-19 patient was diagnosed with acute acalculous cholecystitis and a multidisciplinary team decided to perform a percutaneous transhepatic biliary drainage (PTBD) as the first treatment. SARS-CoV-2 RNA was not found in the bile fluid. Because of deterioration of the patient's clinical conditions, laparoscopic cholecystectomy had to be performed and since the gallbladder was gangrenous, the severe inflammation made surgery difficult to perform.DiscussionAcalculous cholecystitis was related with mechanical ventilation and prolonged total parenteral nutrition, in this case the gangrenous histopathology pattern and the gallbladder wall ischemia was probably caused by vascular insufficiency secondary to severe acute respiratory distress syndrome of COVID-19 pneumonia. The percutaneous transhepatic gallbladder drainage (PTBD) was performed according to Tokyo Guidelines because of high surgical risk. Laparoscopic cholecystectomy was next performed due to no clinical improvement. The absence of viral RNA in the bile highlights that SARS-CoV-2 is not eliminated with the bile while it probably infects small intestinal enterocytes which is responsible of gastrointestinal symptoms such as anorexia, nausea, vomiting, and diarrhoea.ConclusionsAlthough the lack of evidence and guidelines about the management of patient with acute cholecystitis during COVID-19 pandemic, laparoscopic cholecystectomy, at most preceded by PTGBD on high surgical risk patients, remains the gold standard for the treatment of acute cholecystitis on COVID-19 patients.
机译:介绍我们在Covid-19患者上报告了一个极其罕见的胆囊炎。在我们的知识中,这是在Covid-19患者上进行的腹腔镜胆囊切除术的第一份报告。卡卡西亚Covid-19患者的挑战被诊断出患有急性的胆囊炎,并且多学科团队决定进行经皮的转发胆道引流(PTBD)第一次治疗。在胆汁液中未发现SARS-COV-2 RNA。由于患者的临床条件恶化,必须进行腹腔镜胆囊切除术,因为胆囊是恶性的,因此严重的炎症使手术难以进行。讨论性胆囊炎与机械通气和延长的全肠化营养有关,在这种情况下,在这种情况下是恶意组织病理学图案和胆囊壁缺血可能是由Covid-19肺炎的严重急性呼吸窘迫综合征中的血管功能不全引起的。由于手术风险高,根据东京指南进行经皮胸腔胆囊引流(PTBD)。下次由于无临床改善而进行腹腔镜胆囊切除术。胆汁中没有病毒RNA突出显示SARS-COV-2没有用胆汁消除,而它可能感染了胃肠道,恶心,呕吐和腹泻等胃肠症状的小肠肠细胞。虽然缺乏证据关于在Covid-19大流行期间患者患者患者管理的指导方针,腹腔镜胆囊切除术期最多在高手术危险患者中均为PTGBD,仍然是Covid-19患者对急性胆囊炎治疗的金标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号